Literature DB >> 28447064

The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study.

Malinda Itchins1, Nick Pavlakis1.   

Abstract

Entities:  

Year:  2017        PMID： 28447064      PMCID： PMC5388629          DOI： 10.21037/tgh.2017.02.02

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  14 in total

1.  Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Authors:  Nick Pavlakis; Katrin M Sjoquist; Andrew J Martin; Eric Tsobanis; Sonia Yip; Yoon-Koo Kang; Yung-Jue Bang; Thierry Alcindor; Christopher J O'Callaghan; Margot J Burnell; Niall C Tebbutt; Sun Young Rha; Jeeyun Lee; Jae-Yong Cho; Lara R Lipton; Mark Wong; Andrew Strickland; Jin Won Kim; John R Zalcberg; John Simes; David Goldstein
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

2.  Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability.

Authors:  Nobuki Miyamoto; Hiroyuki Yamamoto; Hiroaki Taniguchi; Chie Miyamoto; Mariko Oki; Yasushi Adachi; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Cancer Lett       Date:  2007-03-19       Impact factor: 8.679

3.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Authors:  Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

Review 4.  Update on metastatic gastric and esophageal cancers.

Authors:  Manish A Shah
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

5.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Authors:  Shuichi Hironaka; Shinya Ueda; Hirofumi Yasui; Tomohiro Nishina; Masahiro Tsuda; Takehiko Tsumura; Naotoshi Sugimoto; Hideki Shimodaira; Shinya Tokunaga; Toshikazu Moriwaki; Taito Esaki; Michitaka Nagase; Kazumasa Fujitani; Kensei Yamaguchi; Takashi Ura; Yasuo Hamamoto; Satoshi Morita; Isamu Okamoto; Narikazu Boku; Ichinosuke Hyodo
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

6.  Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Authors:  Jin Li; Shukui Qin; Jianming Xu; Jianping Xiong; Changping Wu; Yuxian Bai; Wei Liu; Jiandong Tong; Yunpeng Liu; Ruihua Xu; Zhehai Wang; Qiong Wang; Xuenong Ouyang; Yan Yang; Yi Ba; Jun Liang; Xiaoyan Lin; Deyun Luo; Rongsheng Zheng; Xin Wang; Guoping Sun; Liwei Wang; Leizhen Zheng; Hong Guo; Jingbo Wu; Nong Xu; Jianwei Yang; Honggang Zhang; Ying Cheng; Ningju Wang; Lei Chen; Zhining Fan; Piaoyang Sun; Hao Yu
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

7.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

8.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962
View more
  2 in total

1.  Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.

Authors:  Caiyun Nie; Yunduan He; Huifang Lv; Ming Gao; Xiaohui Gao; Beibei Chen; Weifeng Xu; Jianzheng Wang; Yingjun Liu; Jing Zhao; Xiaobing Chen
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

Review 2.  Tumor vessel normalization and immunotherapy in gastric cancer.

Authors:  Xianzhe Yu; Shan He; Jian Shen; Qiushi Huang; Peng Yang; Lin Huang; Dan Pu; Li Wang; Lu Li; Jinghua Liu; Zelong Liu; Lingling Zhu
Journal:  Ther Adv Med Oncol       Date:  2022-07-18       Impact factor: 5.485
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.